182 related articles for article (PubMed ID: 36334390)
1. Efficacy and safety of Reyanning mixture in patients infected with SARS-CoV-2 Omicron variant: A prospective, open-label, randomized controlled trial.
Xu X; Zhou S; Chen C; Li J; Wu H; Jin G; Zhou J; Wang G; Cao M; Sun D; Zhang W; Peng W; Pu Y; Sun Y; Fang B; Xu J
Phytomedicine; 2023 Jan; 108():154514. PubMed ID: 36334390
[TBL] [Abstract][Full Text] [Related]
2. Reyanning Mixture on Asymptomatic or Mild SARS-CoV-2 Infection in Children and Adolescents: A Randomized Controlled Trial.
Xu XR; Zhou S; Jin GQ; Wu HZ; Li JH; Zhou J; Peng W; Zhang W; Sun D; Fang BJ
Chin J Integr Med; 2023 Oct; 29(10):867-874. PubMed ID: 37523100
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Huashi Baidu Granules in Treating Patients with SARS-CoV-2 Omicron Variant: A Single-Center Retrospective Cohort Study.
Chen CY; Zhang W; Xu XR; Pu YT; Tu YD; Peng W; Yao X; Zhou S; Fang BJ
Chin J Integr Med; 2024 Feb; 30(2):107-114. PubMed ID: 37222827
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study.
Xu X; Wu H; Jin G; Huang J; Li J; Zhou J; Cao M; Sun D; Zhang W; Peng W; Pu Y; Chen C; Sun Y; Yang H; Zhou S; Fang B
Phytomedicine; 2023 Mar; 111():154665. PubMed ID: 36641977
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of clinical characteristics and prognosis of 4 264 patients with asymptomatic and mild novel coronavirus infections in Shanghai].
Xu X; Sun D; Cao M; Zhang W; Pu Y; Chen C; Sun Y; Zhou S; Fang B
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 May; 34(5):449-453. PubMed ID: 35728842
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant.
Liu C; Wu X; Yang H; Xu X; Chen C; Wu L; Zhang W; Shi H; Fei Y; Sun Y; Wu H; Zhou S; Fang B
Front Pharmacol; 2023; 14():1185122. PubMed ID: 37547325
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
[TBL] [Abstract][Full Text] [Related]
9. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
[TBL] [Abstract][Full Text] [Related]
12. Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial.
Xu J; Song J; Xie Z; Yang J; Wu D; Liu F; Zhao Y; Zang H; Zhao Y
Medicine (Baltimore); 2023 Dec; 102(51):e36714. PubMed ID: 38134107
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
14. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
15. [Randomized double-blind parallel controlled multicenter trial of Reyanning Mixture in treatment of acute tonsillitis].
Lyu J; Yang C; Wang LX; Xie YM; Yu XQ; Gu L; Gao F; Zhang JX; Yu XK
Zhongguo Zhong Yao Za Zhi; 2020 Jul; 45(14):3282-3291. PubMed ID: 32726041
[TBL] [Abstract][Full Text] [Related]
16. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
17. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics and related factors of viral nucleic acid negative conversion in children infected with Omicron variant strain of SARS-CoV-2].
Yin R; Lu Q; Jiao JL; Lin K; Wang C; Yuan L; Ding Y; Dong N; Wang BJ; Niu YH; Fang YS; Liu W; Sun YF; Zou B; Zhang XE; Xiao P; Sun L; Du X; Zhu YY; Dong XY
Zhonghua Er Ke Za Zhi; 2022 Dec; 60(12):1307-1311. PubMed ID: 36444435
[No Abstract] [Full Text] [Related]
20. Influencing factors of nucleic acid negative conversion in patients with mild and common COVID-19 induced by the Omicron variant of SARS-COV-2.
Chen Y; Chen Z; Wang X; Xiong H; Shuang F; Liu X
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 51(6):731-737. PubMed ID: 36915975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
